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Abstract
Background
Better knowledge of the efficacy and safety of single-dose 40 mg/kg oral praziquantel in pre-
school-age children is required, should preventive chemotherapy programs for schistosomi-
asis be expanded to include this age group.
Methodology
We analyzed individual participant-level data from 16 studies (13 single-arm or cohort stud-
ies and three randomized trials), amounting to 683 preschool-age children (aged <6 years)
and 2,010 school-age children (aged 6–14 years). Children had a documented Schistosoma
mansoni or S. haematobium infection, were treated with single 40 mg/kg oral praziquantel,
and assessed between 21 and 60 days post-treatment. Efficacy was expressed as
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Principal findings
Preschool-age children had significantly lower baseline Schistosoma egg counts and more
losses to follow-up compared to school-age children. No difference in efficacy was found
between preschool- and school-age children using a general linear model of individual-par-
ticipant ERR with baseline log-transformed egg count as covariate and study, age, and sex
as fixed variables, and a mixed model with a random effect on the study. Safety was
reported in only four studies (n = 1,128 individuals); few AEs were reported in preschool-age
children 4 and 24 hours post-treatment as well as at follow-up. Three severe but not serious
AEs were recorded in school-age children during follow-up.
Conclusions/significance
There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious
and less safe in preschool-age children compared to school-age children, with the caveat
that only few randomized comparisons exist between the two age groups. Preventive che-
motherapy might therefore be extended to preschool-age children, with proper monitoring of
its efficacy and safety.
Author summary
Schistosomiasis is a diseases caused by helminths (parasitic worms) which affects the
intestinal and urogenital systems. In areas where schistosomiasis is endemic, the disease is
controlled by the large scale distributing of praziquantel, primarily targeting school-age
children. Younger children (preschool-age) too might be affected by schistosomiasis, but
are currently not receiving praziquantel within treatment campaigns. Instead, preschool-
age children are treated on a case-by-case basis because the current praziquantel formula-
tion is not adapted to young children. Questions have also been raised as to whether the
standard dose of 40 mg/kg given once is effective in preschool-age children. To answer
this question, we collected individual-participant data from a series of studies in which 40
mg/kg of praziquantel had been given to children with intestinal or urinary schistosomia-
sis, and compared its efficacy and tolerability across age-groups. Since few direct compari-
sons had been made, we used statistical tools to make these comparisons. We found no
evidence that treatment is less efficacious in preschool- than in school-age children and
conclude that 40 mg/kg praziquantel may be given to preschool-age children in large-
scale programs. When this happens, efficacy and tolerability will have to be closely
monitored.
Introduction
The global schistosomiasis control strategy relies upon preventive chemotherapy with prazi-
quantel, primarily targeting school-age children. In moderate- and high-risk communities,
treatment is also extended to adults [1]. Of note, preschool-age children contribute a
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considerable fraction of the total burden of schistosomiasis [2–4]. The current World Health
Organization (WHO) guidelines are that preschool-age children should be treated on a case-
by-case basis upon diagnosis of infection due to a lack of an age-appropriate formulation of
praziquantel [5]. WHO is considering the inclusion of preschool-age children in preventive
chemotherapy with praziquantel, should an appropriate formulation of praziquantel become
available [5–7]. The reason is that the current formulation (large, bitter tasting 600 mg tablets),
although often crushed and dissolved in practice, is unsuited for use in young children, and
hence, efforts are underway to develop an orally dispersible tablet formulation for young chil-
dren [8, 9]. Evidence of efficacy and safety of praziquantel in preschool-age children is limited
[5], and it is unclear whether they should receive the same dose (i.e., oral administration at a
single dose of 40 mg/kg body weight) as their school-age counterparts, adolescents, and adults
[10].
To address this issue, we analyzed data from clinical trials and epidemiologic studies that
enrolled preschool- and school-age children who were treated with praziquantel at a single 40
mg/kg oral dose, for which data were available at the individual participant level. This informa-
tion is important both for treatment recommendations and for adapting the strength of prazi-
quantel to be used in pediatric formulation.
Methods
Ethics statement
This is a secondary analysis of published work. Ethical approval and written (or oral) informed
consent have been reported in the original papers [5, 11–30].
Datasets
Based on a scoping paper [31], the WHO Special Programme for Research and Training in
Tropical Diseases (TDR) and the Department of Control of Neglected Tropical Diseases at
WHO contacted investigators for the availability of suitable patient datasets from studies that
enrolled preschool-age children. The investigators of 23 clinical studies [5, 11–30] agreed to
share data with the specific purpose of pooled analyses aimed at answering the PICO (popula-
tion, intervention, control, and outcome) question below. The datasets were curated in order
to allow for the pooled analysis. One article [18] contained two different studies, which were
analyzed separately. Subsequently, studies were further assessed as to their eligibility for inclu-
sion in the analysis (whole study or subset of participants). In this dataset, studies are identified
by the name of the main data contributor and the year the study was conducted.
PICO question
In preschool-age children, is praziquantel given at 40 mg/kg body weight in a single oral dose
as efficacious as it is in school-age children in reducing Schistosoma infection (measured as egg
counts in stool or urine)?
Study and patient inclusion criteria
The following inclusion criteria were employed: (i) treatment with praziquantel 40 mg/kg
body weight; (ii) participant’s age 0–14 years; (iii) confirmed infection with Schistosoma man-
soni, S. haematobium, or S. japonicum, as determined by the presence of eggs in stool or urine;
and (iv) treatment outcome assessed at follow-up visit between 21 and 60 days post-treatment.
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Assessment of methodological quality
Key characteristics of studies were extracted from the published articles. The methodologic
quality was assessed through the Cochrane Collaboration’s [32] risk of bias table, including
items such as random sequence generation (selection bias), allocation concealment (selection
bias), blinding of participants and personnel (performance bias), blinding of outcome assess-
ment (detection bias), incomplete outcome data (attrition bias), and selective reporting
(reporting bias). We also prepared funnel plots to check for publication bias, stratified by
Schistosoma species.
Assessment of heterogeneity
We investigated heterogeneity by examining the forest plots, and carried out sensitivity analy-
ses by calculating the pooled mean difference of individual egg reduction rate (ERR) between
preschool- and school-age children.
Assessment of reporting bias
We compared studies included in this analysis with those identified by a prior scoping review
[31]. However, only studies for which individual participant-level data were made available
could be included in the present analysis.
Statistical methods
Summarizing infection intensity. The arithmetic mean (AM) eggs per gram of stool
(EPG) was calculated at pre- and post-treatment for S. mansoni by multiplying the mean indi-
vidual fecal egg counts (FECs) obtained by a single, duplicate, or quadruplicate Kato-Katz
thick smears (41.7 mg) by a factor of 24 [33, 34]. For S. haematobium, egg counts were pre-
sented as eggs per 10 ml of urine [34].
Measuring efficacy. Drug efficacy was expressed as AM egg reduction rate (ERR) (the dif-
ference in AM egg counts between pre- and post-treatment assessments), cure rate (CR, pro-
portion of cases with zero egg counts post-treatment), and mean of individual ERR, with 95%
confidence intervals (CIs). Individual ERRs were calculated as the ratio of the difference
between the pre- and post-treatment EPG or eggs per 10 ml urine, multiplied by 100. In this
analysis, no change or increase in egg counts post-treatment indicates an ERR = 0 (no reduc-
tion). CIs were determined using a bootstrap resampling method (with replacement) over
1,000 replicates. This methodology has been described in greater detail elsewhere [35]. Accord-
ing to WHO guidelines, the reference target efficacy for AM-ERR is�95% [36].
The distribution of the individual ERRs was plotted by using histograms of the frequencies
and scatterplot of the cumulative frequencies as ‘centiles plots’. Forest plots were utilized to
visualize mean individual ERRs by age categories. Results are presented separately by Schisto-
soma species.
Statistical analyses. Modeling of baseline log-transformed egg counts was performed
with age categories and country as fixed factors in a general linear model, and with country as
a random factor in a mixed model. Modeling of the individual ERRs was carried out through a
general linear model and mixed models. Separate models were fitted for S. mansoni and S.
haematobium.
In the general linear model, the level of infection at baseline was included as covariate (log-
transformed baseline EPG for S. mansoni and eggs per 10 ml of urine for S. haematobium).
Fixed variables were country, participant’s sex, and three age categories: (i) 0 to<6 years; (ii) 6
to<10 years; and (iii) 10–14 years to more accurately reflect the age-range of the included
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studies (see below), or preschool-age (0 to<6 years) versus school-age children (6–14 years).
Mixed models were further fitted with a random effect on the country. Sensitivity analyses
were conducted with the same models by removing the baseline log-transformed egg counts.
Pairwise differences (with a Tukey adjustment) in least square means (LSM) were per-
formed for each of the age groups. This post-hoc comparison was allowed by the implicit net-
work of possible preschool- and school-age children comparisons across all studies (S1 Fig)
[37, 38].
All tests were two-tailed and a p-value of 5% was deemed statistically significant. Calcula-
tions and analyses were performed by using Revman version 5.3.5 (The Nordic Cochrane Cen-
tre; Copenhagen, Denmark) (The Cochrane Collaboration, 2014) and SAS system version 9.3
(SAS Institute; Cary, United States of America).
Safety was assessed using reported adverse events (AEs), classified as mild, moderate, or
severe. We extrapolated the number of patients exposed and assessed for safety at 4 and 24
hours post-treatment and at the end of follow-up and calculated the frequency of those with at
least one AE. We also report the total number and type of AEs for each age-category and by
severity.
The PRISMA guidelines were used and followed for reporting the current work. The
PRISMA checklist is attached as supplementary material.
Results
Data were available from 23 studies with children treated either for S. mansoni, S. haemato-
bium, or S. japonicum infection with single 40 mg/kg oral praziquantel (Table 1 and S1 Table,
including diagnostic approach used). The study flowchart (overall and by age-group; pre-
school- versus school-age children) is presented in Fig 1. Details by study and age-group (pre-
school- versus school-age) are summarized in Table 2.
Exclusions
A total of seven studies and four study arms were excluded for the following reasons. First, six
studies were excluded as a whole, as they did not meet one or more of the inclusion criteria
(two studies because the praziquantel dose was not 40 mg/kg [20, 28], and four studies because
the duration of follow-up was >60 days) [5, 18, 29]. Second, we excluded study arms that were
outside the set criteria, namely those who received a praziquantel dose higher or lower than 40
mg/kg [13, 14, 22], or were outside the 0–14 years age range [22]. Third, we excluded partici-
pants with S. japonicum infection because only one preschool-child was enrolled in Xu et al.
[30] out of six participants, and none in Olliaro et al. [22] (Table 1).
The remaining 16 studies and study groups enrolled a total of 4,484 (63%) children who
were treated with single 40 mg/kg oral praziquantel: preschool-age children (n = 1,422; 32%)
and school-age children (n = 3,062; 68%). Of note, five studies [11, 15, 22, 27] did not enroll
preschool-age children. Sousa-Figueiredo et al. [25] enrolled both preschool- and school-age
children aged 6–10 years, and Olliaro et al. [22] included only school-age children aged 10–14
years (Table 1). Overall 75% of the treated children (n = 2,675) were followed up and had a
measurable outcome 21–60 days post-treatment; 665 preschool-age children and 2,010 school-
age children. More losses to follow-up occurred among the preschool-age children compared
to their older counterparts (33% versus 21%, p<0.001).
Out of the 16 studies included in the analyses, three were randomized controlled trials
(RCT) and 13 were single-arm intervention or cohort studies. The RCTs were at low risk of
selection bias with computer-generated block randomization, adequate allocation conceal-
ment, and blinding of either participants, personnel, or outcome assessment. The single-arm
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Table 1. Characteristics of available datasets and numbers of participants enrolled and included in the meta-analysis (0% analysed indicate excluded studies with
0% analysed).
Author, year
of study [Ref.]
Country Total
enrolled
Follow-up
duration
(days)
Dose
(mg/
kg)
Species Enrolled (age
0 to < 6
years)
Enrolled
(age 6 to
<10 years)
Enrolled
(age 10 to
14 years)
%
analysed
of
enrolled
Reason for exclusion
Coulibaly,
2011 [12]
Coˆte
d’Ivoire
53 21 40 S. mansoni
S.
haematobium
53 100%
Coulibaly,
2017 [13]
Coˆte
d’Ivoire
84 21 20
40
60
S. mansoni 40 22 21 96% Dose = 20 & 60 mg/kg
and placebo excluded
Coulibaly,
2018 [14]
Coˆte
d’Ivoire
346 21 20
40
60
S.
haematobium
170 112 56 98% Dose = 20 & 60 mg/kg
and placebo excluded
Garba, 2007
[15]
Niger 659 42 40 S. mansoni
S.
haematobium
370 289 83%
Tohon, 2008
[39]
Niger 877 21 40 S.
haematobium
209 211 83%
Garba, 2013
[16]
Niger 243 42 40 S. mansoni
S.
haematobium
243 95%
N’Goran, 2000
[20]
Coˆte
d’Ivoire
354 52 80 S.
haematobium
5 174 129 0% Dose = 80 mg/kg
Landoure´,
2006 [18]
Mali 415 365 40 S. mansoni
S.
haematobium
413 553 0% Follow-up >60 days
Landoure´,
2009 [18]
Mali 415 182 40 S. mansoni
S.
haematobium
409 0% Follow-up >60 days
Garba, 1996
[17]
Niger 560 60 40 S.
haematobium
77 86 76 63%
Mutapi, 2010
[19]
Zimbabwe 535 42 40 S. mansoni
S.
haematobium
132 351 83 30%
Campagne,
2008 [11]
Niger 114 30 40 S. mansoni
S.
haematobium
1 37 66 87%
Olds, 1999 [21] Kenya 415 45 40 S.
haematobium
2 49 67 100%
Olliaro, 2007
[22]
Brazil
Mauritania
Philippines
856 21 40
60
S. mansoni
S.
haematobium
S.japonicum
534 36% S. japonicum (Philippines,
no preschool-age children)
and dose = 60 mg/kg
excluded
Raso, 2004
[23]
Mali 545 42 40 S. mansoni 4 12 22 100%
Sacko, 2009 [5] Mali 415 180 40 S. mansoni
S.
haematobium
415 0% Follow-up >60 days
Scherrer, 2007
[24]
Coˆte
d’Ivoire
49 20 40 S. mansoni 6 22 21 100%
Sousa-
Figueiredo,
2012 [25]
Uganda 880 21 6040 S. mansoni 693 187 35%
Stete, 2010
[26]
Coˆte
d’Ivoire
545 21 40 S.
haematobium
1 20 56 100%
Utzinger, 1997
[27]
Coˆte
d’Ivoire
209 28 40 S. mansoni 27 56 100%
(Continued)
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intervention or cohort studies were at unclear risk of bias as there was no randomization, no
allocation concealment, and no blinding. Furthermore, no study mentioned if sampling was
stratified for preschool- and school-age children. Regarding incomplete outcome data and
selective reporting items of the risk of bias tables, attrition rate was generally low (Figs 2 and
3). The funnel plots showed extensive publications bias (Figs 4 and 5). However, for both S.
mansoni and S. haematobium, half of the studies could not be plotted because they were non-
comparative, hence a mean difference and a standard error of the mean between preschool-
and school-age children could not be calculated (see also Figs 2 and 3).
Of the 2,010 evaluable school-age children, 988 were aged 6 to<10 years (382 (56%) pre-
senting with S. mansoni and 301 (44%) with S. haematobium infections), and 1,022 were aged
Table 1. (Continued)
Author, year
of study [Ref.]
Country Total
enrolled
Follow-up
duration
(days)
Dose
(mg/
kg)
Species Enrolled (age
0 to < 6
years)
Enrolled
(age 6 to
<10 years)
Enrolled
(age 10 to
14 years)
%
analysed
of
enrolled
Reason for exclusion
Utzinger, 1998
[28]
Coˆte
d’Ivoire
253 28 60 S. mansoni 129 124 0% Dose = 60 mg/kg
Wami, 2014
[29]
Zimbabwe 303 84 40 S. mansoni
S.
haematobium
109 148 46 0% Follow-up >60 days
Xu, 2007 [30] China 880 90 40 S. japonicum 1 5 0% S. japonicum only one
preschool-age child
TOTAL 10,005 2,361 2,368 2,415
https://doi.org/10.1371/journal.pntd.0008277.t001
Fig 1. Study flowchart (PSAC: preschool-age children; SAC: school-age children).
https://doi.org/10.1371/journal.pntd.0008277.g001
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10–14 years (667 (33%) S. mansoni and 1,343 (67%) S. haematobium infections) (Table 3).
Intensity of infection at baseline and treatment outcomes expressed as ERRs calculated as AM
as well as CRs are presented in Table 4, stratified by Schistosoma species for the three age
groups (details by study in Supplementary Tables 2 and 3, stratified by Schistosoma species).
The baseline intensity of infection analyses adjusted on study and sex showed a significant dif-
ference between age groups with higher counts in the school- than the preschool-age children
(Fig 6, S4 Table, S4 Table, S5 Table, and S6 Table). A significant difference in baseline egg
counts between boys and girls was found for S. haematobium but not for S. mansoni (S6
Table). The age distribution of participants by Schistosoma species can be found in S2 Fig.
The AM-ERRs are also presented graphically as forest plots in Figs 7 and 8 for S. mansoni
and S. haematobium, respectively against the�95% WHO threshold for efficacy [36]. Overall,
6/13 (2/6 for S. mansoni and 4/7 for S. haematobium) of the study groups with participants in
the age-group under 6 years (preschool-age) met the WHO efficacy threshold, compared to 5/
Table 2. Number of subjects in the 16 studies enrolled and analysed.
Author, year [Ref.] Enrolled
PSAC
Enrolled
SAC
Enrolled PSAC
+SAC
Evaluable
PSAC
Evaluable
SAC
Evaluable PSAC
+SAC
With follow-up
PSAC
With follow-
up SAC
With follow-up
PSAC+SAC
Coulibaly 2011 [12] 53 0 53 53 53 53 53
Coulibaly 2017 [13] 40 43 83 38 42 80 38 42 80
Coulibaly 2018 [14] 170 168 338 37 37 74 37 37 74
Garba 2007 [15] 0 659 659 659 659 549 549
Garba 2009 [17] 0 420 420 360 360 347 347
Garba 2013 [16] 243 0 243 243 243 231 231
Garba 1996 [17] 77 162 239 114 228 342 61 160 221
Mutapi 2010 [19] 132 434 566 101 434 535 21 149 170
Campagne, 2008
[11]
1 103 104 100 100 90 90
Olds, 1999 [21] 2 116 118 2 116 118 2 116 118
Olliaro 2007 [22] 0 534 534 190 190 190 190
Raso 2004 [23] 4 34 38 4 34 38 4 34 38
Scherrer 2007 [24] 6 43 49 6 43 49 6 43 49
Sousa-Figueiredo
2012 [25]
693 187 880 395 128 523 211 94 305
Stete 2010 [26] 1 76 77 1 76 77 1 76 77
Utzinger 1997 [27] 0 83 83 83 83 83 83
TOTAL 1,422 3,062 4,484 994 2,530 3,524 665 2,010 2,675
https://doi.org/10.1371/journal.pntd.0008277.t002
Fig 2. S. mansoni studies forest plot of mean egg counts and bias table.
https://doi.org/10.1371/journal.pntd.0008277.g002
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14 (1/6 for S. mansoni and 4/8 for S. haematobium) of the children aged 6 to<10 years and 2/
14 (0/6 for S. mansoni and 2/8 for S. haematobium) of the children aged 10–14 years).
The centile distribution of the individual-patient ERRs is displayed in Figs 9 and 10 for S.
mansoni and S. haematobium, respectively.
The percentage of patients with ERRs = 0 (no decrease), between>0 and<100%, and
100% (corresponding to the CR) in the different age categories is represented in the bar graphs
for each study and in Table 5.
A majority of ERRs are in the 100% category (i.e. ‘cured’ from the current infection). For
preschool-age children as well as younger school-age children (aged 6 to 10 years) almost 80%
of the subjects have an ERR above 70%, whereas the results per studies are highly hetegeneous
in the 10–14 years old for both S. mansoni and S. haematobium as ascertained by the very dif-
ferent cumulative curves. There was a significant difference between age groups (p<0.001) for
both species, though for different reasons: for S. mansoni the difference is driven by preschool-
age children having about twice as many non-responders as school-age children (10.2% versus
5.1%), while for S. haematobium more preschool-age children were cured (100% ERR: 77.4%
versus 60.2%). However, no age difference was seen in treatment outcomes after multivariable
adjustment in statistical models. The general linear model of individual-participant ERR with
baseline log-transformed egg count as covariate and study, age, and sex as fixed variables did
Fig 3. S. haematobium studies forest plot of mean egg counts and bias table.
https://doi.org/10.1371/journal.pntd.0008277.g003
Fig 4. Studies funnel plot for S. mansoni.
https://doi.org/10.1371/journal.pntd.0008277.g004
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not show any difference in efficacy between age categories in the post-hoc pairwise compari-
sons of marginal means (least squares means) for either S. mansoni or S. haematobium
(Table 6). This was confirmed in a mixed model employing a random effect for each study
(Table 7). Neither baseline egg counts nor duration of follow-up influenced treatment out-
come (S7 Table and S8 Table). Sensitivity analyses with log-transformed baseline egg counts
for both S. mansoni and S. haematobium provided similar results for studies accounted for
Fig 5. Studies funnel plot for S. haematobium.
https://doi.org/10.1371/journal.pntd.0008277.g005
Table 3. Number of subjects analyzed (evaluable subjects with follow-up) by age category and Schistosoma species.
S. mansoni S. haematobium All
Author, year [Ref.] 0 to <6
years
6 to <10
years
10 to 14
years
0 to <6
years
6 to <10
years
10 to 14
years
0 to <6
years
6 to <10
years
10 to 14
years
Coulibaly 2011 [12] 35 0 0 18 0 0 53 0 0
Coulibaly 2017 [13] 38 22 20 0 0 0 38 22 20
Coulibaly 2018 [14] 0 0 0 37 25 12 37 25 12
Garba 2007 [15] 0 99 82 0 211 157 0 310 239
Garba 2009 [15] 0 0 0 0 177 170 0 177 170
Garba 2013 [16] 88 0 0 161 0 0 231 0 0
Garba 1996 [17] 0 0 0 61 85 75 61 85 75
Mutapi 2010 [19] 0 0 0 21 115 34 21 115 34
Campagne, 2008 [11] 0 0 0 0 30 60 0 30 60
Olds, 1999 [21] 0 0 0 2 49 67 2 49 67
Olliaro 2007 [22] 0 0 190 0 0 0 0 0 190
Raso 2004 [23] 4 12 22 0 0 0 4 12 22
Scherrer 2007 [24] 6 22 21 0 0 0 6 22 21
Sousa-Figueiredo 2012 [25] 211 94 0 0 0 0 211 94 0
Stete 2010 [26] 0 0 0 1 20 56 1 20 56
Utzinger 1997 [27] 0 27 56 0 0 0 0 27 56
TOTAL 382 276 391 301 712 631 665 988 1,022
Preschool-age (0 to <6
years)
382 301 665
School-age (6 to 14 years) 667 1,343 2,010
https://doi.org/10.1371/journal.pntd.0008277.t003
PLOS NEGLECTED TROPICAL DISEASES Meta-Analysis of praziquantel efficacy on schistosomiasis in preschool-age children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008277 June 22, 2020 10 / 23
either as fixed factor (general linear model, S4 Table) or as random effect (mixed model, S5
Table).
Safety was reported in 7/16 studies with only four studies [13, 16, 19, 35] reporting on
evaluable patients who had safety data corresponding to participants with follow-up <60 days,
age�14 years, and praziquantel dose of 40 mg/kg (total number assessed on day 1 = 1,128; at
follow-up = 1,065, 94%) (Table 8). Overall, 226 (20%) patients suffered from at least one AE 4
hours after drug intake, 88 (8%) after 24 hours, and 33 (3%) at the treatment follow-up,
Table 4. Intensity of infection at baseline and follow-up, and treatment outcomes expressed as arithmetic mean (AM) egg reduction rate (ERR), cure rate (CR), and
mean individual egg reduction rate (all with 95% confidence intervals) by age category and by Schistosoma species.
Age category Follow-up duration (in
days)
N evaluable Mean EPG at
baseline
Mean EPG at follow-
up
ERR 95%CI CR 95%CI Mean individual
ERR 95%CI
S. mansoni
0 to <6 years 21 290 244.4 51.2 79.1 (67.8; 88.6) 59.7% (54.0%;
65.3%)
48.8 (23.3; 74.3)
0 to <6 years 42 92 109.6 7.5 93.2 (89.5; 96.3) 76.1% (67.4%;
84.8%)
81.1 (70.5; 91.8)
6 to <10
years
21 138 226.4 23.7 89.5 (78.3; 96.3) 71.7% (64.2%;
79.3%)
78.2 (60.8; 95.7)
6 to <10
years
42 138 100.6 26.1 74.1 (65.3; 82.1) 59.4% (51.2%;
67.6%)
64.1 (43.1; 85.1)
10 to 14 years 21 231 21.8 0.8 96.3 (93.2; 98.8) 87.9% (83.7%;
92.1%)
91.6 (84.2; 99.0)
10 to 14 years 42 160 114.4 15.0 86.9 (79.1; 93.3) 66.3% (58.9%;
73.6%)
81.9 (72.3; 91.4)
6 to 14 years 21 369 98.3 9.4 90.5 (81.0; 96.3) 81.8% (77.9%;
85.8%)
93.5 (91.3; 95.7)
6 to 14 years 42 298 108.0 20.1 81.4 (75.4; 86.4) 63.1% (57.6%;
68.6%)
83.4 (79.9; 86.9)
S. haematobium
0 to <6 years 21 56 20.0 0.3 98.4 (96.7; 99.5) 82.1% (72.1%;
92.2%)
94.9 (89.6;
100.2)
0 to <6 years 42 184 37.0 5.2 85.9 (69.1; 98.8) 83.7% (78.4%;
89.0%)
93.9 (90.8; 96.9)
0 to <6 years 60 61 14.9 22.4 -50.4 (-147.3;
34.1)
54.1% (41.6%;
66.6%)
75.7 (65.5; 86.0)
6 to <10
years
21 222 95.0 1.9 98.1 (97.1; 98.8) 57.2% (50.7%;
63.7%)
95.6 (93.7; 97.5)
6 to <10
years
42 405 76.7 17.0 77.9 (67.0; 88.3) 72.1% (67.7%;
76.5%)
92.7 (90.5; 94.9)
6 to <10
years
60 85 79.1 66.5 15.9 (-37.2; 56.0) 22.4% (13.5%;
31.2%)
59.6 (50.0; 69.2)
10 to 14 years 21 238 97.2 5.6 94.2 (88.9; 98.0) 56.7% (50.4%;
63.0%)
93.4 (90.9; 95.8)
10 to 14 years 42 318 87.5 24.3 72.2 (58.1; 83.9) 67.9% (62.8%;
73.1%)
91.3 (88.8; 93.9)
10 to 14 years 60 75 81.4 35.1 57.0 (37.9; 73.1) 25.3% (15.5%;
35.2%)
61.5 (52.2; 70.9)
6 to 14 years 21 460 96.1 3.8 96.0 (93.1; 98.1) 57.0% (52.4%;
61.5%)
94.4 (92.9; 96.0)
6 to 14 years 42 723 81.5 20.2 75.2 (67.6; 82.8) 70.3% (66.9%;
73.6%)
92.1 (90.5; 93.7)
6 to 14 years 60 160 80.2 51.7 35.5 (9.1; 57.3) 23.8% (17.2%;
30.3%)
60.5 (53.8; 67.2)
https://doi.org/10.1371/journal.pntd.0008277.t004
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Fig 6. Baseline intensity of infection analyses adjusted for study and age.
https://doi.org/10.1371/journal.pntd.0008277.g006
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respectively. At least one AE was experienced at 4 hours post-treatment by 19% and 44% of
under 6-year-old children and children aged 10–14 years, respectively. Only one child had an
AE in the 6- to<10-year-old age group. The relative proportions at 24 hours were 5%, 21%,
and 0%. At follow-up, 10% of the children aged 10–14 years reported at least one AE, and
none in the other age-groups.
A total of 370, 272, and 134 AEs were reported on the day of treatment 4 hours after drug
intake, at 24 hours post-treatment, and at the follow-up visit, respectively. At 4 hours, there
were 81 AEs of mild intensity in children aged 0 to<6 years; one mild in the age group 6 to
<10 years; and 228 mild, 159 moderate, and one severe AEs in children aged 10–14 years. At
24 hours, 19 mild AEs in the 0 to<6 year age group; none in the children aged 6 to<10 years;
and 205 mild, 46 moderate, and two severe AEs in the oldest group of children 10–14 years. At
treatment follow-up, a total of 88 mild and 46 moderate AEs were observed in the 10- to
14-year-old age group. The severe AEs were dizziness, anorexia, and diarrhea, but none of the
AEs were judged as serious.
Fig 7. Forest plots of ERR for S. mansoni.
https://doi.org/10.1371/journal.pntd.0008277.g007
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At 4 hours post-treatment, the most frequent AE was abdominal pain (39.7% of AEs), fol-
lowed by diarrhea (14.3%), vomiting (9.5%), headache and dizziness (both 8.4%). At 24 hours,
it was headache (23.2%) then abdominal pain (16.5%), dizziness (15.1%), and diarrhea (11%).
At treatment follow-up, headache (27.6%), abdominal pain (19.4%), anorexia (14.2%), and diz-
ziness (12.7%) were the most frequent AEs.
Discussion
This individual-participant data meta-analysis aimed to assess whether a single 40 mg/kg oral
dose of 40 mg/kg of praziquantel administered to preschool-age children (aged <6 years)
would be as efficacious and safe as in school-age children. This kind of evidence is important.
Indeed, while the current emphasis of preventive chemotherapy is on school-age children [1,
34], preschool-age children are now also recognized to carry a significant burden of disease,
and hence, they are becoming a target for preventive chemotherapy, especially if a pediatric
formulation of praziquantel becomes available [6, 7]. Furthermore, efforts are under way to
strategically move from morbidity control to elimination, which means preventive
Fig 8. Forest plots of ERR for S. haematobium.
https://doi.org/10.1371/journal.pntd.0008277.g008
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chemotherapy might need to be expanded to include all age-groups in order to remove all
untreated reservoirs of infection that contribute to ongoing local transmission [40].
Taken together, our results point to no age-effect on treatment efficacy with the standard
single-dose of 40 mg/kg praziquantel, whether administered to children under the age of 6
years (preschool-age), or to school-age children (aged 6–14 years), or whether the latter group
is further broken down into 6 to less than 10, and 10 through 14 years (as some studies only
included either age-group).
We analyzed data using two models: (i) a general linear model with or without baseline log-
transformed Schistosoma egg counts as covariate and study, age, and sex as cofactors; and (ii) a
mixed model with or without baseline log-transformed egg counts as covariate, age as a fixed
factor, with a random effect for each study. None of these models detected a statistically signifi-
cant difference in the individual ERRs between age categories. These analyses also show that
the lower baseline egg counts found in preschool-age children did not have an effect on treat-
ment outcome, nor did duration of follow-up within the 21–60 day time-frame.
Our conclusions are further supported by the observation that, when using the WHO-rec-
ommended AM-ERR, there is no indication that fewer groups composed of preschool-age
children meet the WHO�95% efficacy threshold compared to school-age children. These
results are in overall agreement with mixed-effect multivariate analysis of aggregated data that
found no significant difference between preschool- and school-age children for CR or geomet-
ric mean ERR for either S. mansoni or S. haematobium after controlling for time of assessment,
Fig 9. Centile distribution of the individual-patient ERRs for S. mansoni.
https://doi.org/10.1371/journal.pntd.0008277.g009
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formulation, intensity of infection, and diagnostic approach [41]. While host factors, like age-
related differences in drug metabolizing activity [42] might play a role in praziquantel metabo-
lism and overall efficacy, increasing the dose to 60 mg/kg may not lead to better efficacy. Two
of the studies conducted in Coˆte d’Ivoire contributing to this analysis, which also studied the
response to placebo and doses ranging from 20 mg/kg to 60 mg/kg, showed a flat dose-
response curve in both preschool- and school-age children infected with S. haematobium and
preschool-children infected with S. mansoni [13, 14]. Another study [22] compared 40 mg/kg
to 60 mg/kg in children aged 10–14 years, and did not find a difference either. Similarly, in an
aggregated-data meta-analysis using a random-effect meta-analysis regression model, a dose-
effect for CR was found up to 40 mg/kg for S. mansoni and 30 mg/kg for S. haematobium with
no benefit in increasing the dose, in school-age children [43].
Treatment with a single 40 mg/kg oral dose of praziquantel was well tolerated, especially in
preschool-age children who experienced fewer and generally only mild AEs when compared
to school-age children. Previous systematic reviews pertaining to the efficacy and safety of pra-
ziquantel for schistosomiasis already showed that praziquantel is safe and AEs usually mild
and self-limiting [41, 44, 45]. It is, however, conceivable that this is a result of underreporting
by younger children, if AEs were not specifically and proactively elicited.
Our study has several limitations. First, out of 16 studies included in the analysis, 13 were
single-arm thus with an unclear risk of bias concerning selection of participants. Second, the
studies enrolled selectively different age groups, so we used the principles of network meta-
Fig 10. Centile distribution of the individual-patient ERRs for S. haematobium.
https://doi.org/10.1371/journal.pntd.0008277.g010
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analysis to compare participant outcomes in different groups, which were not necessarily
enrolled at the same site and time, and might thus not be comparable. Third, safety and tolera-
bility at large were also generally underreported. Fourth, no information is available for S.
japonicum. A more general methodological issue is the limitations of counting eggs in excreta
in young children, and the imperfect correlation between egg shedding and worm burden,
which would be better reflected by antigen-detection methods. [46] However, the significance
and comparability of results of efficacy studies based on antigen-detection methods vis-à-vis
direct egg-detection remains unclear.
In conclusion, based on the data presented here, there is no indication that preventive che-
motherapy with single-dose 40 mg/kg praziquantel would be less efficacious and tolerated in
preschool-age children than it is in school-age children. However, these conclusions are drawn
from an available, limited body of evidence, which is only a tiny fraction of the overall use of
praziquantel, with only a few studies designed for direct comparisons between age groups.
Whether and when preschool-age children will be exposed systematically to preventive chemo-
therapy, close monitoring of efficacy as well as safety will be required. This in particular
Table 5. Individual patient egg reduction rate (ERR) by Schistosoma species and age group.
S. mansoni S. haematobium
Age ERR n % n %
0 to <6 years 0% 39 10.2 19 6.3
0<ERR<100 100 26.2 49 16.3
100% 243 63.6 233 77.4
6 to <10 years 0% 20 7.3 44 6.2
0<ERR<100 75 27.2 230 32.3
100% 181 65.6 438 61.5
10 to 14 years 0% 14 3.6 34 5.4
0<ERR<100 68 17.4 227 36.0
100% 309 79.0 370 58.6
Χ2 p-value <0.001 <0.001
6 to 14 years 0% 34 5.1 78 5.8
0<ERR<100 143 21.4 457 34.0
100% 490 73.5 808 60.2
Χ2 p-value <0.001 <0.001
https://doi.org/10.1371/journal.pntd.0008277.t005
Table 6. Post-hoc pairwise comparisons between age categories, general linear model.
S. mansoni individual egg reduction rates S. haematobium individual egg reduction rates
Effect Category Mean SD Adj P Mean SD Adj P
Age 10 to 14 years 0.937 0.0224 0.892 0.0134
6 to <10 years 0.925 0.0205 0.903 0.0130
0 to <6 years 0.884 0.0238 0.929 0.0203
Age 6 to 14 years 0.930 0.0162 0.898 0.0113
0 to <6 years 0.887 0.0223 0.928 0.0202
Pairwise comparisons
Age 10 to 14 years 6 to <10 years 0.0119 0.0280 0.906 -0.0106 0.0134 0.710
10 to 14 years 0 to <6 years 0.0533 0.0372 0.324 -0.0368 0.0273 0.368
6 to <10 years 0 to <6 year 0.0414 0.0288 0.322 -0.0262 0.0266 0.585
Age 6 to 14 years 0 to <6 years 0.0432 0.0285 0.130 -0.0304 0.0260 0.243
https://doi.org/10.1371/journal.pntd.0008277.t006
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considering preschool-age children have about twice as high rates of non-responders in the
individual-patient ERR analysis than older children.
It should also be noted that the WHO-recommended 95% ERR threshold was not met in
many studies, which calls for improved dosing and delivery strategies.
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